Immunitybio Inc
IBRX
$8.44-2.31%
End of day · as of Sep 26, 2026, 2:16 AM ET
Mkt cap
$7.88B
EV/Sales
68.8
P/E ratio
N/A
FY2025 Revenue
$113.29M
EPS (TTM)
$-0.95
Gross Margin (FY2025)
99.34%
Profit Margin (FY2025)
-310.18%
Beta
0.07
Div yield
N/A
Sector
Healthcare
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
Use this IBRX research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full IBRX income, balance, and cash tables.
† Total Debt: Derived from short-term debt only (no total or long-term debt stored).
Immunitybio Inc (IBRX) is a biotechnology company in the Healthcare sector.
Latest cached Immunitybio Inc (IBRX) revenue for Dec 31, 2025 was $113.3M. Net income was -$351.4M. Statements: https://lician.com/financials/ibrx
Immunitybio Inc (IBRX) market capitalization is $7.88B on the latest cached snapshot.
Immunitybio Inc (IBRX) cached previous close $8.64; day range $8.41 – $8.84; volume 5,758,722. Session quote: https://lician.com/quote/ibrx
Immunitybio Inc (IBRX) latest cached earnings event is "IBRX earnings" on Aug 4, 2026. Earnings calendar: https://lician.com/earnings
The latest cached IBRX filing is 8-K · Oct 14, 2026. Filings: https://lician.com/sec/ibrx